Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04791215 · ClinicalTrials.gov registry record
Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab
A clinical trial, sponsored by Columbia University.
- Terminated
- Registry status
- 10
- Enrollment target
NCT04791215 is a clinical trial that was terminated before completion, run by Columbia University. The registered enrollment target is 10 participants.
The verdict
NCT04791215 was terminated before completion, sponsored by Columbia University.
- TERMINATED
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to learn how to use blood tests to better predict how patients with non-small cell lung cancer, who are taking pembrolizumab for cancer treatment, will respond to treatment with pembrolizumab, and to understand how the immune system and cancer interact. Tests will be performed on tumor tissue and blood samples, and imaging assessments will be reviewed in order to monitor how well each patient responds to treatment. This is an observational study, so participants will not receive cancer treatment, other than the treatment received as standard of care.
Interventions
- OTHER Observational
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-02-01 |
| Est. Completion | 2023-04-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04791215
The ClinicalTrials.gov registry entry for NCT04791215 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Observational is the first listed.
NCT04791215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04791215 about?
NCT04791215 is a clinical study titled "Circulating Tumor DNA Alterations in Non-small Cell Lung Cancer Patients Treated With Pembrolizumab". The purpose of this study is to learn how to use blood tests to better predict how patients with non-small cell lung cancer, who are taking pembrolizumab for cancer treatment, will respond to treatment with pembrolizumab, and to understand how the immune system and cancer interact. Tests will be pe...
What is the current status of trial NCT04791215?
This trial is currently terminated. The enrollment target is 10 participants. The study started on 2020-02-01. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT04791215?
The interventions under investigation include: Observational (OTHER).
Who is sponsoring clinical trial NCT04791215?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.